Economic Evaluations of Granulocyte Colony-Stimulating Factor: In the Prevention and Treatment of Chemotherapy-Induced Neutropenia

PharmacoEconomics

Volumn 21, Issue 18, 2003, Pages 1295-1313

  Esser, Marc ^a,b   Brunner, Helmut ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG COST; DRUG MEGADOSE; ECONOMICS; FEBRILE NEUTROPENIA; HEALTH ECONOMICS; HEMATOPOIETIC SYSTEM TUMOR; HOSPITAL COST; HUMAN; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0346100492     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03262329     Document Type: Review

References (58)

1. Hollingshead LM, Goa KL. Recombinant granulocyte-colony stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991 Aug; 42 (2): 300-30
2. Adams JR, Lyman GH, Djubegovic B, et al. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002; 3 (9): 1273-81
3. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998 Sep; 16 (9): 3179-90
4. Bennett CL, Smith TJ, Hillner BE, et al. Free-riding and prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 1995 Sep 13; 14 (9): 2457-63
5. Bennett CL, Smith TJ, Weeks JC. et al. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. J Clin Oncol 1996 Sep; (14): 2511-20
6. Frampton JE. Faulds D. Filgrastim: a reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 1996 Jan; 9 (1): 76-96
7. Dickersin K, Scherer R, Levebvre C. Identifying relevant studies for systematic reviews. BMJ 1994 Nov 12; 309 (6964): 1286-91
8. Kraemer HC, Andrews G. A nonparametric technique for meta-analysis effect size calculation. Psychol Bull 1982; 91 (2): 404-12
9. Bennett CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol 2000 Feb; 34 (2): 92-6
10. Chouaid C, Bassinet L, Fuhrmann C, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998 Aug; 16 (8): 2700-7
11. Dranitsaris G, Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leuk Lymphoma 1995 Mar; 17 (1-2): 139-45
12. Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma. Pharmacoeconomics 1997 Jun; 11 (6): 566-77
13. Glaspy JA, Bleeker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993; 29A Suppl. 7: 23-30
14. Le Du I, Lebert P, Le Corre P, et al. Étude pharmacoé conomique du G-CSF dans le traitement des lymphomes malins non hodgkiniens. J Pharm Clin 1996 Jun; 15 (2): 113-7
15. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoetic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993 Mar 17; 85 (6): 488-93
16. Messori A, Trippoli S, Tendi E. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996 Apr; 21 (2): 57-63
17. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994 Jun; 12 (6): 1245-50
18. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lympoblastic leukemia. N Engl J Med 1997 Jun 19; 336 (25): 1781-7
19. Riikonen P, Rahalia J, Salonvaara M, et al. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995 May; 13 (3): 289-94
20. Rubino C, Laplanche C, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after introduction chemotherapy in children with non-Hodgkin's lymphoma. J Natl Cancer Inst 1998 May; 90 (10): 750-5
21. Schröder CP, de Vries EG, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother 1999 May; 43 (5): 741-3
22. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994; 5 Suppl. 2: 127-32
23. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991 Jul; 325 (3): 164-70
24. Brice P, Godin S, Libert O, et al. Influence du facteur de croissance granulocytaire sur le coût des autogreffes de moelle en onco-hématologie. Presse Med 1994 Oct; 23 (33): 1512-5
25. Clark RE, Shlebak AA, Creagh MD. Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leuk Lymphoma 1994 Dec; 16 (1-2): 141-6
26. Duncan N, Hewetson M, Atra A, et al. An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children. Pharmacoeconomics 1997 Feb; 11 (2): 169-4
27. Kucharski AJ, Ghalie R, Greenstein S, et al. The clinical effectiveness and financial impact of utilizing peripheral blood progenitor cells as rescue therapy following autologous bone marrow transplant. Int J Technol Assess Health Care 1996; 12 (1): 172-9
28. Lee SJ, Weller E, Alyea EP, et al. Efficacy and costs of granulocyte colony-stimulating factor in allogenic T-cell depleted bone marrow transplantation. Blood 1998 Oct 15; 92 (8): 2725-9
29. Souêtre E, Quing W, Pénelaud PF. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 1996; 32A (7): 1162-5
30. Uyl-de Groot CA, Richel DJ, Rutten FF. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 30A (11): 1631-5
31. Dunlop DJ, Fitzsimons EJ, McMurray A, et al. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994 Nov; 70 (5): 943-5
32. Lee SM, Radford JA, Dobson L, et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998 Apr; 77 (8): 1294-9
33. McQuaker IG, Hunter AE, Pacey S, et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997 Feb; 15 (2): 451-7
34. Ojeda E, Garcia-Bustos J, Aguado M, et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999 Sep; 24 (6): 601-7
35. Stinson TJ, Adams JR, Bishop MR, et al. Economic analysis of a phase III study of G-CSF vs placebo following stem cell transplantation. Bone Marrow Transplant 2000 Sep; 26 (6): 663-6
36. Tarella C, Castellino C, Locatzelli F, et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998 Feb; 21 (4): 401-7
37. Viens P, Genre D, Protière C, et al. Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer. Eur Cytokine Netw 1998 Mar; 9(1): 93-8
38. Flynn TN, Kelsey SM, Hazel DL, et al. Cost effectiveness of amphotericin B plus G-CSF compared to amphotericin monotherapy: treatment of presumed deep fungal infection in neutropenic patients in the UK. Pharmacoeconomics 1999 Nov; 16 (5 Pt 2): 543-50
39. García-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001 Jan; 93 (1): 31-8
40. Mateos RJ, Gonzáles JB, Lloret CA, et al. Aproximación a un análisis coste-efectividad del tratamiento con G-CSF en tumores no sólidos. Farm Clin 1994 Mar; 11 (2): 122-34
41. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony stimulating factors. J Natl Cancer Inst 1995 Jun; 87 (11): 803-8
42. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997 Mar; 15 (3): 1163-70
43. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug; 313 (7052): 275-83
44. Lyman GH, Kuderer NM, Djubegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002 Apr; 112 (5): 406-11
45. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62 Suppl. 1: 1-15
46. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence based clinical practice guidelines. J Clin Oncol 2000 Oct; 18 (20): 3558-85
47. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematological malignancies and solid tumors. J Clin Oncol 1997 Aug; 15 (8): 2981-95
48. Lyman GH, Kuderer N, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998 Nov; 34 (12): 1857-64
49. Standaert B, Goldstone J, Lu J, et al. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data. Pharmacoeconomics 2002; 20 (10): 665-74
50. Bessmertny O, Cairo MS. Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay? J Pediatr Hematol Oncol 2003 Jun; 25 (6): 435-40
51. Silber JH, Fridman M, Shpilsky A, et al. Modeling the cost-effectiveness of granulocyte-colony stimulating factor in early-stage breast cancer. J Clin Oncol 1998 Jul; 16 (7): 2435-44
52. Balducci L, Hardy CL, Lyman GH. Hematopoietic growth factors in the older cancer patients. Curr Opin Hematol 2001 May; 8 (3): 170-87
53. Lyman GH. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. Eur J Cancer 2000 Apr; 36 Suppl. 1: 15-21
54. Faucher C, Corroller AG, Blaise D, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994 Dec; 14 (6): 895-901
55. de Azevedo AM, Nucci M, Maiolino A, et al. A randomized multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002 May; 29 (9): 745-51
56. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer 2002 Apr; 10 (3): 181-8
57. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 1994 Oct; 121 (7): 492-501
58. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997 Jun; 336 (25): 1776-80